Trial
NCT05135845
Combination of Capmatinib + Spartalizumab in Advanced Oesogastric Adenocarcinoma
Phase IISUSPENDEDSAFETYConfidence: HIGH
Sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
—
Condition
Oesophageal Adenocarcinoma
Intervention
Capmatinib
Why stopped
Sponsor decision up DSMB advice due to unfavorable toxicity profile
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-02-03